EUVIMEDEUVIMED entdecken
VergleichsstudieMetaanalyse

Comparative Efficacy of GnRHa Monotherapy vs Combination Therapy for Central Precocious Puberty

Chang-En Tsai, Hsien-Yu Fan iD, Meng-Che Tsai iD, Hsin-Yuan Chang, Chien-Ming Lin, Chen Yang, Jia-Woei Hou, Yang-Ching Chen iD

The Journal of Clinical Endocrinology & Metabolism · 21.01.2026 · 111 (2) · e603-e618

DOI: 10.1210/clinem/dgaf617 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 12.11.2025. Verfasst von Chang-En Tsai und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan. Hauptthemen laut MEDLINE: Puberty, Precocious, Gonadotropin-Releasing Hormone. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 114 Literaturangaben. Gefördert von: Higher Education Sprout Project of the Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Central precocious puberty (CPP) can reduce adult height. Studies comparing the efficacy of gonadotropin-releasing hormone analogue (GnRHa) monotherapy with combination therapies show inconsistency.

Objective

This work aims to synthesize evidence comparing the effects of GnRHa monotherapy and combination therapies on height-related outcomes in children with CPP.

Methods

Data sources included PubMed, EMBASE, Cochrane Library, Wanfang Data, and CNKI through December 31, 2024. Study selection included randomized controlled trials (RCTs) and cohort studies involving children aged 12 years or younger with CPP or early puberty, reporting height-related outcomes and a follow-up of 6 months or more. Data were pooled using common- or random-effects models and reported as mean differences (MDs) with 95% CIs for primary outcomes, including height gain (adult height minus pretreatment predicted adult height [PAH]), PAH change (posttreatment PAH minus pretreatment PAH), and growth velocity (GV) in children with CPP.

Results

A total of 70 studies (30 RCTs and 40 cohort studies; 5266 children) were included. Growth hormone (GH) combination therapy significantly improved PAH change (MD, 3.48 cm; 95% CI, 2.98-3.98) and GV (MD, 1.82 cm/y; 95% CI, 1.32-2.31) in RCTs, and height gain (MD, 3.81 cm; 95% CI, 2.77-4.84) and PAH change (MD, 3.06 cm; 95% CI, 2.26-3.86) in cohort studies, compared with GnRHa monotherapy. However, high heterogeneity remains across outcomes, even after subgroup analysis of treatment duration and GH dose, which limits the certainty of these findings. Stanozolol, oxandrolone, and estrogen showed improved growth outcomes, although evidence was limited. Longer treatment durations and higher GH doses were associated with greater benefits.

Conclusion

GH combination therapy enhances growth outcomes in children with CPP compared to GnRHa alone. Stanozolol, oxandrolone, and estrogen show promise but require further research. Personalized combination regimens and additional long-term RCTs are needed, particularly involving male patients and non-GH adjunctive therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Puberty, PrecociousGonadotropin-Releasing HormoneHumansDrug Therapy, CombinationChildBody HeightFemaleTreatment OutcomeMaleRandomized Controlled Trials as TopicHuman Growth HormoneChild, Preschool

Stichwörter der Autor:innen

central precocious pubertyearly pubertygonadotropin-releasing hormone analoguegrowth hormonehuman growth

Substanzen

Gonadotropin-Releasing HormoneHuman Growth Hormone

Autor:innen und Institutionen

  • School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.
  • School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei 110, Taiwan.
  • Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan.
  • Department of Pediatrics, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan.
  • Department of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, Taipei 115, Taiwan.
  • Department of Pediatrics, Taipei Medical University Hospital, Taipei 110, Taiwan.

ORCID-Profile: Hsien-Yu Fan, Meng-Che Tsai, Yang-Ching Chen

Förderung

  • Higher Education Sprout Project of the Ministry of Education

Zitieren

APA

Tsai, C. E., Fan, H. Y., Tsai, M. C., Chang, H. Y., Lin, C. M., Yang, C., Hou, J. W., & Chen, Y. C. (2026). Comparative Efficacy of GnRHa Monotherapy vs Combination Therapy for Central Precocious Puberty. The Journal of Clinical Endocrinology & Metabolism, 111(2), e603-e618. https://doi.org/10.1210/clinem/dgaf617

Vancouver

Tsai CE, Fan HY, Tsai MC, Chang HY, Lin CM, Yang C, et al. Comparative Efficacy of GnRHa Monotherapy vs Combination Therapy for Central Precocious Puberty. The Journal of Clinical Endocrinology & Metabolism. 2026;111(2):e603-e618. doi:10.1210/clinem/dgaf617

BibTeX
@article{Tsai2026,
  author = {Tsai, Chang-En and Fan, Hsien-Yu and Tsai, Meng-Che and Chang, Hsin-Yuan and Lin, Chien-Ming and Yang, Chen and Hou, Jia-Woei and Chen, Yang-Ching},
  title = {Comparative Efficacy of GnRHa Monotherapy vs Combination Therapy for Central Precocious Puberty},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  volume = {111},
  number = {2},
  pages = {e603--e618},
  doi = {10.1210/clinem/dgaf617}
}
Kostenlos starten →